Correction: Monitoring  EGFR -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer

Teresa Morán; Eudald Felip; Joaquim Bosch-Barrera; Itziar de Aguirre; Jose Luis Ramirez; Carles Mesia; Enric Carcereny; Diana Roa; Elia Sais; Yolanda García; Remei Blanco; Silvia Sanchez; Claudia Rosa Villacorta; Cristina Queralt; Jose María Velarde; Rafael Rosell

doi:10.18632/oncotarget.26855

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer

PDF | How to cite

Oncotarget. 2019; 10:2576-2576. https://doi.org/10.18632/oncotarget.26855

Metrics: PDF 1698 views | ?

Teresa Morán¹, Eudald Felip¹, Joaquim Bosch-Barrera², Itziar de Aguirre³, Jose Luis Ramirez³, Carles Mesia⁴, Enric Carcereny¹, Diana Roa², Elia Sais², Yolanda García⁵, Remei Blanco⁶, Silvia Sanchez⁷, Claudia Rosa Villacorta⁷, Cristina Queralt³, Jose María Velarde⁸ and Rafael Rosell³

¹ Medical Oncology Department, Catalan Institute of Oncology - Badalona, Hospital Universitari Germans Trias i Pujol, Badalona, Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
² Medical Oncology Department, Catalan Institute of Oncology-Girona, Hospital Universitari Doctor Trueta Girona, Girona, Spain
³ Molecular Biology Laboratory of Cancer Dr. Rosell, Can Ruti Campus: Institute Germans Trias i Pujol (IGTP), Catalan Institute of Oncology, Badalona, Spain
⁴ Medical Oncology Department, Catalan Institute of Oncology - Hospital Duran i Reynalds, l’Hospitalet de Llobregat, Barcelona, Spain
⁵ Medical Oncology Department, Hospital Parc Taulí, Sabadell, Barcelona, Spain
⁶ Medical Oncology Department, Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain
⁷ Research Nurse Team, Catalan Institute of Oncology - Badalona, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
⁸ Statistics Department, Fundació Germans Trias i Pujol, Badalona, Spain
⁹ Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

Published: April 02, 2019

This article has been corrected: The correct affiliation information is given below:

Original article: Oncotarget. 2018; 9:27074-27086. https://doi.org/10.18632/oncotarget.25478

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26855

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer